Management of Postpartum Hemorrhage
Immediately administer tranexamic acid 1 g IV over 10 minutes as soon as PPH is diagnosed (within 3 hours of birth), alongside standard resuscitation and uterotonic therapy—this is a life-saving intervention that reduces maternal death from bleeding. 1
Initial Recognition and Immediate Actions
Postpartum hemorrhage is defined as blood loss ≥500 mL after vaginal delivery or ≥1000 mL after cesarean section, or any bleeding causing hemodynamic instability 1. The moment PPH is suspected:
- Call for help and activate your massive hemorrhage protocol
- Start fluid resuscitation immediately if bleeding persists after first-line uterotonics or if clinical signs of severity are present 2
- Administer tranexamic acid 1 g IV (100 mg/mL at 1 mL/min over 10 minutes) within 3 hours of birth 1
- Give a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours 1
- Critical timing caveat: Benefit decreases by 10% for every 15-minute delay; no benefit after 3 hours and potentially harmful beyond this window 1
- Give tranexamic acid for ALL causes of PPH—uterine atony, trauma, retained placenta—not just when uterotonics fail 1
Sequential Treatment Algorithm
Step 1: Identify the Cause (The "4 T's")
While initiating treatment, determine the cause since uterine atony accounts for 70.6% of cases 3:
- Tone (uterine atony): Most common cause
- Trauma (genital tract lacerations): 16.9% of cases 3
- Tissue (retained placenta/products): 16.4% of cases 3
- Thrombin (coagulopathy): 2.7% of cases 3
Step 2: First-Line Interventions (Simultaneously)
- Uterine massage and bimanual compression
- Manual uterine examination with antibiotic prophylaxis 2
- Careful visual inspection of the lower genital tract for trauma
- Oxytocin 5-10 IU slowly IV or IM, followed by maintenance infusion (not exceeding 40 IU cumulative) 2
Step 3: Second-Line Medical Management (Within 30 Minutes)
If oxytocin fails to control bleeding:
- Sulprostone is recommended within 30 minutes of PPH diagnosis 2
- Maintain fibrinogen ≥2 g/L during active hemorrhage 2
- Target hemoglobin >8 g/dL with RBC transfusion 2
- Administer RBC, fibrinogen, and FFP without awaiting laboratory results if severe 2
Step 4: Mechanical Interventions
If pharmacological treatment fails:
- Intrauterine balloon tamponade before proceeding to surgery or interventional radiology 2
- This is effective and less invasive than surgical options 4
Step 5: Invasive Interventions
If bleeding persists despite above measures:
- Arterial embolization or surgical intervention (brace sutures, arterial ligation, or hysterectomy) 1
- Progress from less to more invasive interventions sequentially 1
Critical Supportive Care
Throughout management:
- Prevent and treat hypothermia: Warm all infusion solutions, blood products, and use active skin warming 2
- Administer oxygen in severe PPH 2
- Monitor vital signs continuously
- Avoid manual placental removal in out-of-hospital settings unless severe uncontrolled hemorrhage occurs 5
Important Contraindications and Caveats
Avoid tranexamic acid in women with known thromboembolic events during pregnancy 1. However, this is the only clear contraindication—do not withhold it based on theoretical concerns.
Common pitfall: Waiting to give tranexamic acid until "other treatments fail." The 2018 WHO guideline explicitly changed this—tranexamic acid should be given early for ALL PPH cases, regardless of suspected cause 1. The WOMAN trial of over 20,000 women demonstrated reduced bleeding-related mortality when given within 3 hours 1.
Key strength of evidence: The WHO strong recommendation 1 is based on the WOMAN trial, which included nearly 200 hospitals across 21 countries and demonstrated mortality reduction with early tranexamic acid use. This represents the highest quality evidence available and supersedes older recommendations that reserved tranexamic acid for refractory cases.
The evidence consistently shows that early, aggressive, bundled treatment saves lives—uterine atony is the most common cause (70.6% of cases), but 7.8% of women have multiple concurrent causes 3, supporting the use of comprehensive treatment bundles rather than sequential single interventions.